Drug Database · Clinicians

Epirubicin

Brands (45) Epribenz-10, Epribenz-50, Neoquabin…Show all

US brand (reference label): Ellence; not a Philippine-registered brand.

Antineoplastic agent (anthracycline); Antineoplastic (cell cycle-nonspecific agent); and others PH FDA category

Rx · Prescription drug54 PH productsPNF-listedVAT-exempt (some products)
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 0a03c798-a652-4895-b29c-3b521a89ba42, version date July 24, 2026 (Ellence · Pharmacia & Upjohn Company LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • ELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1) ] .
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE ELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1)]. ELLENCE is an anthracycline topoisomerase inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer (1).

Contraindications

4 CONTRAINDICATIONS ELLENCE is contraindicated in patients with:

  • Severe myocardial insufficiency [see Warnings and Precautions (5.1)]
  • Recent myocardial infarction or severe arrhythmias, or previous treatment with maximum cumulative dose of anthracyclines [see Warnings and Precautions (5.1)]
  • Severe persistent drug-induced myelosuppression [see Warnings and Precautions (5.4)]
  • Severe hepatic impairment (defined as Child-Pugh Class C or serum bilirubin level greater than 5 mg/dL) [see Warnings and Precautions (5.5)]
  • Severe hypersensitivity to ELLENCE, other anthracyclines, or anthracenediones [see Adverse Reactions (6.1)]
  • Severe myocardial insufficiency (4).
  • Recent myocardial infarction (4).
  • Severe persistent drug-induced myelosuppression (4).
  • Severe hepatic impairment (4).
  • Severe hypersensitivity to ELLENCE, other anthracyclines, or anthracenediones (4).
US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

  • The recommended starting dose of ELLENCE is 100 to 120 mg/m 2. Dosage reductions are possible when given in certain combinations (2.2).
  • Administer intravenously in repeated 3- to 4-week cycles, either total dose on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle (2.2).
  • Consider use of antiemetics when given in conjunction with other emetigenic drugs (2.1).
  • Patients administered the 120 mg/m 2 regimen of ELLENCE should receive prophylactic antibiotic therapy (2.1).
  • Adjust dosage after the first treatment cycle based on hematologic and nonhematologic toxicities (2.3).
  • Reduce dose in patients with hepatic impairment (2.3, 8.6).
  • Consider lower doses in patients with severe renal impairment (2.3, 8.7).
2.1 Important Administration Instructions

2.1 Important Administration Instructions When possible, to reduce the risk of developing cardiotoxicity in patients receiving ELLENCE after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as trastuzumab, delay ELLENCE-based therapy until the other agents have cleared from the circulation [see Warnings and Precautions (5.1)]. Antiemetics may reduce nausea and vomiting; consider use of antiemetics before administration of ELLENCE or when clinically indicated, particularly when given in conjunction with other emetigenic drugs [see Adverse Reactions (6.1)].

Patients administered the 120 mg/m 2 regimen of ELLENCE should receive prophylactic antibiotic therapy.

2.2 Recommended Dose

2.2 Recommended Dose The recommended dose of ELLENCE is 100 to 120 mg/m 2 administered as an intravenous bolus [see Dosage and Administration (2.4)]. The following regimens are recommended: CEF-120: Cyclophosphamide 75 mg/m 2 oral on Days 1 to 14 ELLENCE 60 mg/m 2 intravenously on Days 1 and 8 5-Fluorouracil 500 mg/m 2 intravenously on Days 1 and 8 Repeat every 28 days for 6 cycles FEC-100: 5-Fluorouracil 500 mg/m 2 intravenously on Day 1 ELLENCE 100 mg/m 2 intravenously on Day 1 Cyclophosphamide 500 mg/m 2 intravenously on Day 1 Repeat every 21 days for 6 cycles Administer ELLENCE in repeated 3- to 4-week cycles.

The total dose of ELLENCE may be given on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle.

2.3 Dose Modifications

2.3 Dose Modifications ELLENCE dosage adjustments for hematologic and non-hematologic toxicities within a cycle of treatment, is based on nadir platelet counts <50,000/mm 3, absolute neutrophil counts (ANC) <250/mm 3, neutropenic fever, or Grades 3/4 nonhematologic toxicity. Reduce ELLENCE Day 1 dose in subsequent cycles to 75% of the Day 1 dose given in the current cycle.

Delay Day 1 chemotherapy in subsequent courses of treatment until platelet counts are ≥100,000/mm 3, ANC ≥1500/mm 3, and nonhematologic toxicities have recovered to ≤ Grade 1. Cardiac Toxicity Discontinue ELLENCE in patients who develop signs or symptoms of cardiomyopathy [see Warnings and Precautions (5.1)]. Bone Marrow Dysfunction Consider administering a lower starting dose (75–90 mg/m 2) for heavily pretreated patients, patients with pre-existing bone marrow depression, or in the presence of neoplastic bone marrow infiltration [see Warnings and Precautions (5.4)].

For patients receiving a divided dose of ELLENCE (Day 1 and Day 8), the Day 8 dose should be 75% of Day 1 if platelet counts are 75,000–100,000/mm 3 and ANC is 1000 to 1499/mm 3. If Day 8 platelet counts are <75,000/mm 3, ANC <1000/mm 3, or Grades 3/4 nonhematologic toxicity has occurred, omit the Day 8 dose. Hepatic Impairment In patients with elevated serum AST or serum total bilirubin concentrations [see Warnings and Precautions (5.5) and Clinical Pharmacology (12.3)], reduce dosage as follows:

  • Bilirubin 1.2 to 3 mg/dL or AST 2 to 4 times upper limit of normal 1/2 of recommended starting dose
  • Bilirubin > 3 mg/dL or AST > 4 times upper limit of normal 1/4 of recommended starting dose Renal Impairment Consider lower doses in patients with severe renal impairment (serum creatinine > 5 mg/dL) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].
2.4 Preparation and Administration Precautions

2.4 Preparation and Administration Precautions Preparation Storage of the solution for injection at refrigerated conditions can result in the formation of a gelled product. This gelled product will return to a slightly viscous to mobile solution after 2 to a maximum of 4 hours equilibration at controlled room temperature (15–25°C).

Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. ELLENCE is a cytotoxic drug. Follow applicable special handling and disposable procedures 1 [see References (15)]. Incompatibilities Avoid prolonged contact with any solution of an alkaline pH as it will result in hydrolysis of the drug.

Do not mix ELLENCE with heparin or fluorouracil due to chemical incompatibility that may lead to precipitation. ELLENCE can be used in combination with other antitumor agents, but do not mix with other drugs in the same syringe. Administration Administer ELLENCE into the tubing of a freely flowing intravenous infusion (0.9% sodium chloride or 5% glucose solution).

Patients receiving initial therapy at the recommended starting doses of 100–120 mg/m 2 should generally have ELLENCE infused over 15–20 minutes. For patients who require lower ELLENCE starting doses due to organ dysfunction or who require modification of ELLENCE doses during therapy, the ELLENCE infusion time may be proportionally decreased, but should not be less than 3 minutes.

This technique is intended to minimize the risk of thrombosis or perivenous extravasation, which could lead to severe cellulitis, vesication, or tissue necrosis. A direct push injection is not recommended due to the risk of extravasation, which may occur even in the presence of adequate blood return upon needle aspiration.

Venous sclerosis may result from injection into small vessels or repeated injections into the same vein [see Warnings and Precautions (5.3)]. Storage Use ELLENCE within 24 hours of first penetration of the rubber stopper. Discard any unused solution.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations, pharmacokinetics)

8.7 Renal Impairment No significant alterations in the pharmacokinetics of epirubicin or its major metabolite, epirubicinol, have been observed in patients with serum creatinine <5 mg/dL. Consider lower doses in patients with severe renal impairment (serum creatinine >5 mg/dL), as a reduction in plasma clearance was reported in these patients [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)]. Patients on dialysis have not been studied.

Renal Impairment No significant alterations in the pharmacokinetics of epirubicin or its major metabolite, epirubicinol, have been observed in patients with serum creatinine < 5 mg/dL. A 50% reduction in plasma clearance was reported in four patients with serum creatinine ≥ 5 mg/dL [see Warnings and Precautions (5.6) and Dosing and Administration (2.2)].

Patients on dialysis have not been studied. Effect of Paclitaxel The administration of paclitaxel (175–225 mg/m 2 as a 3-hour infusion) immediately before or after epirubicin (90 mg/m 2 as bolus) caused variable increases in the systemic exposure (mean AUC) of epirubicin ranging from 5% to 109%. At same doses of epirubicin and paclitaxel, the mean AUC of the inactive metabolites of epirubicin (epirubicinol and 7-deoxy-aglycone) increased by 120% and 70%, respectively, when paclitaxel was immediately administered after epirubicin.

Epirubicin had no effect on the exposure of paclitaxel whether it was administered before or after paclitaxel. Effect of Docetaxel The administration of docetaxel (70 mg/m 2 as 1-hour infusion) immediately before or after epirubicin (90 mg/m 2 as bolus) had no effect on the systemic exposure (mean AUC) of epirubicin. However, the mean AUC of epirubicinol and 7-deoxy-aglycone increased by 22.5% and 95%, respectively, when docetaxel was immediately administered after epirubicin compared to epirubicin alone.

Epirubicin had no effect on the exposure of docetaxel whether it was administered before or after docetaxel. Effect of Cimetidine Coadministration of cimetidine (400 mg twice daily for 7 days starting 5 days before chemotherapy) increased the mean AUC of epirubicin (100 mg/m 2) by 50% and decreased its plasma clearance by 30%.

Drugs metabolized by cytochrome P-450 enzymes No systematic in vitro or in vivo evaluation has been performed to examine the potential for inhibition or induction by epirubicin of oxidative cytochrome P-450 isoenzymes.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment Epirubicin is eliminated by both hepatic metabolism and biliary excretion and clearance is reduced in patients with hepatic dysfunction. Do not treat patients with severe hepatic impairment with ELLENCE [see Contraindications (4)]. Reduce the starting dose for patients with less severe hepatic impairment [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of ELLENCE have not been established in pediatric patients. Pediatric patients may be at greater risk for anthracycline-induced acute manifestations of cardiotoxicity or late cardiovascular dysfunction. The pharmacokinetics of epirubicin in pediatric patients have not been evaluated.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Clinical experience in patients who were 65 years of age and older who received ELLENCE chemotherapy regimens for primary breast cancer showed no overall differences in safety and effectiveness compared with younger patients. In elderly female patients, closely monitor for increased toxicity due to the risk of decreased clearance of epirubicin [see Clinical Pharmacology (12.3)].

Administration

2.1 Important Administration Instructions When possible, to reduce the risk of developing cardiotoxicity in patients receiving ELLENCE after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as trastuzumab, delay ELLENCE-based therapy until the other agents have cleared from the circulation [see Warnings and Precautions (5.1) ]. Antiemetics may reduce nausea and vomiting; consider use of antiemetics before administration of ELLENCE or when clinically indicated, particularly when given in conjunction with other emetigenic drugs [see Adverse Reactions (6.1) ]. Patients administered the 120 mg/m 2 regimen of ELLENCE should receive prophylactic antibiotic therapy.

2.4 Preparation and Administration Precautions Preparation Storage of the solution for injection at refrigerated conditions can result in the formation of a gelled product. This gelled product will return to a slightly viscous to mobile solution after 2 to a maximum of 4 hours equilibration at controlled room temperature (15–25°C). Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. ELLENCE is a cytotoxic drug. Follow applicable special handling and disposable procedures 1 [see References (15) ]. Incompatibilities Avoid prolonged contact with any solution of an alkaline pH as it will result in hydrolysis of the drug. Do not mix ELLENCE with heparin or fluorouracil due to chemical incompatibility that may lead to precipitation. ELLENCE can be used in combination with other antitumor agents, but do not mix with other drugs in the same syringe. Administration Administer ELLENCE into the tubing of a freely flowing intravenous infusion (0.9% sodium chloride or 5% glucose solution). Patients receiving initial therapy at the recommended starting doses of 100–120 mg/m 2 should generally have ELLENCE infused over 15–20 minutes. For patients who require lower ELLENCE starting doses due to organ dysfunction or who require modification of ELLENCE doses during therapy, the ELLENCE infusion time may be proportionally decreased, but should not be less than 3 minutes. This technique is intended to minimize the risk of thrombosis or perivenous extravasation, which could lead to severe cellulitis, vesication, or tissue necrosis. A direct push injection is not recommended due to the risk of extravasation, which may occur even in the presence of adequate blood return upon needle aspiration. Venous sclerosis may result from injection into small vessels or repeated injections into the same vein [see Warnings and Precautions (5.3) ]. Storage Use ELLENCE within 24 hours of first penetration of the rubber stopper. Discard any unused solution.

US FDA label

Dosage forms

Philippines

  • Lyophilized powder for injection: 10 mg, 50 mg
  • ) concentrate solution for injection: 2 mg/mL (10 mg/5 mL, 2 mg/mL (50 mg/25 mL
  • Lyophilized powder for solution for iv infusion: 100 mg
  • Lyophilized powder for iv infusion: 50 mg, 100 mg
  • Powder for injection: 10 mg, 50 mg
  • ) solution for intravenous/intravesical injection: 2 mg/mL (50 mg/25 mL
  • Concentrate for injection: 2 mg/mL
  • Concentrate solution for injection: 2 mg/mL
  • Lyophilized powder for infusion: 50 mg
  • Lyophilized powder for intravenous injection: 50 mg

and 2 more forms; see the products table.

Registered products in the Philippines

54 products registered with the Food and Drug Administration (FDA) Philippines list Epirubicin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Epiribucin Hydrochloride (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products54
Philippine FDA-registered products for Epirubicin
Package insert
BrubicinEpirubicin hydrochloride
50 mg Lyophilized Powder for Injection (IV)In 25 mL-Capacity Type I Clear Tubular Glass Vial with Grey Butyl Rubber Stopper and Aluminum Flip Off Seal (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-8940-01
Sep 19, 2031
Carcirub-10Epirubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)5 mL- capacity USP Type I clear glass vial with bromobutyl rubber stopper and red aluminium flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8942
Sep 17, 2030
Carcirub-50Epirubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)30 mL- capacity USP Type I clear glass vial with bromobutyl rubber stopper and red aluminium flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Globo Asiatico Enterprises, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8941
Sep 17, 2030
Cytobin-10Epirubicin hydrochloride
10 mg Lyophilized Powder for IV InjectionUSP Type I with bromo butyl slotted rubber plug and red aluminum flip-off seal x 5 ml (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Orange Biotec Inc.
DRP-10919
Dec 16, 2031
Cytobin-50Epirubicin hydrochloride
50 mg Lyophilized Powder For IV Infusion30 mL-capacity USP type I glass vial with bromo butyl slotted rubber plug and red aluminum flip-off seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Suhitas Pharmaceuticals Inc.Trader: N/A
DRP-10918
Dec 16, 2026
EberubiEpirubicin Hydrochloride
2 mg/mL Concentrate Solution for Injection (IV/Intravesical)Type I colorless glass vial with rubber stopper and sealed with aluminium crimp caps (Box of 5 mL, 25 mL, 50 mL, 100 mL)
RxVAT-exempt
Ebewe Pharma Ges.m.b.H. Nfg. KGAustria
Sandoz Philippines Corporation
DRP-11025
Jan 6, 2027
EP MycinEpirubicin Hydrochloride
2 mg/mL Solution for InjectionUSP Type I Clear and Colorless Glass Vial x 5 mL and 25 mL (Box of 10's)
RxVAT-exempt
Boryung CorporationRepublic of Korea
Endure Medical, Inc.
DR-XY33140
Mar 27, 2029
Ephevex 50Epirubicin Hydrochloride
50 mg Lyophilized Powder For Injection (I.V)30 mL-capacity USP Type I glass vial with bromobutyl rubber stopper, aluminum seal and red flip-off cap (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Ve Pharma Inc.Trader: Vexxa Lifesciences FZE
DRP-18088
May 4, 2031
Epi Spal-L 50Epirubicin hydrochloride
2 mg/mL (50 mg / 25 mL) Solution for Intravenous/Intravesical InjectionUSP Type I clear glass vial with 20 mm grey chlorobutyl rubber closure and 20 mm orange aluminum flip off seal x 25 mL (Box of 1's)
RxVAT-exempt
SP Accure Labs Pvt. Ltd.India
Hexagon Pharmaceuticals
DRP-15701
Aug 29, 2029
Epibiocin-10Epirubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)5-mL capacity USP Type I Clear glass vial with bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-11385
Mar 9, 2032
Epibiocin-50Epirubicin Hydrochloride
50mg Lyophilized Powder for Injection (IV)30-mL capacity USP Type I Clear glass vial with bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifescienceIndia
Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-11386
Mar 9, 2027
Epichlor-50Epirubicin (as hydrochloride)
50 mg Lyophilized Powder for Intravenous InjectionType I Glass Vial x 25 mL (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Medethix, Inc.
DRP-4473
Jun 13, 2031
EpicinEpirubicin hydrochloride
2 mg/mL Concentrate for Injection (IV/Intravesical)5 mL, 10 mL, 25 mL Type I Amber Glass Vial with Gray Chlorobutyl Rubber Stopper and Aluminum Seal with Red Cap (Box of 1's)
RxVAT-exempt
TTY Biopharma Company Limited Chungli FactoryTaiwan
American Taiwan Biopharma Philippines, Inc.
DR-XY46074
Oct 6, 2029
Epicord 10Epirubicin
2mg/mL (10mg/5mL) Concentrate Solution for Injection (IV/Intravesical)5 mL Type I clear glass vial with teflon stopper, aluminum cap and white flip-off seal (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Importer: Accord Healthcare Limited-Philippine Branch Office
DRP-11237
Feb 16, 2027
Epicord 50Epirubicin
2 mg/mL (50 mg/25 mL) Concentrate Solution for Injection (IV/Intravesical)30 ml Type I clear glass vial with teflon stopper, aluminum cap and royal blue flip-off seal (Box of l's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited - Philippine Branch OfficeImporter: Accord Healthcare Limited-Philippine Branch Office
DRP-11433
Mar 11, 2027
EpiGetEpiribucin HydrochlorideVariant spelling
10 mg Lyophilized Powder for Injection (I.V.)USP Type I clear glass vial x 5 mL (net content), with gray bromobutyl rubber stopper, aluminum seal and red flip-off cap with plastic tray (Box of 1's)
Rx
Biozenta Lifescience Pvt. Ltd.India
2MG Incorporated
DRP-18270
Jun 9, 2031
Epinotic-10Epirubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)10 mL USP Type I Clear Glass Vial (Box of 1 's)
RxVAT-exempt
Adley Formulations Pvt. Ltd.India
Asa Life Philippines Limited Inc
DRP-5775
Nov 19, 2029
Epinotic-50Epirubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)30 mL USP Type I Clear Glass Vial (Box of 1 's)
RxVAT-exempt
Adley Formulations Pvt. Ltd.India
Asa Life Philippines Limited Inc
DRP-5774
Nov 19, 2029
EpirimedEpirubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)30 mL-Capacity USP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Red Aluminum Flip-Off Seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Detoxicare Philippines, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8941-01
Sep 17, 2030
EpirolEpirubicin hydrochloride
50 mg Lyophilized Powder for Injection (IV)In 25 mL-Capacity Type I Clear Tubular Glass Vial with Grey Butyl Rubber Stopper and Aluminum Flip Off Seal (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Genace Pharma DistributorImporter: Bliss Pharma Distribution And Consultancy Corp.
DRP-8940
Nov 10, 2030
Epirubisaph-100Epirubicin hydrochloride
100 mg Lyophilized Powder for IV Infusion50 mL-Capacity USP Type I Clear Glass Vial with Grey Chlorobutyl Rubber Stopper and Light Blue colored Aluminum Flip-Off Seal (Box of 1's).
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-13651
Mar 23, 2028
EpirunEpirubicin hydrochloride
50 mg Lyophilized Powder for Injection (IV)In 25 mL-Capacity Type I Tubular Glass Vial with Grey Butyl Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-8940-02
Sep 17, 2031
EpiruzetEpirubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)30-mL capacity USP Type I Clear glass vial with bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Pharma 518, Inc.Importer: Ambica International Corporation
DRP-11384-01
Mar 9, 2032
Episaphcin-10Epirubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)5 mL USP Type I glass vial with grey bromobutyl rubber stopper and blue flip-off cap (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-13072
Nov 25, 2027
Episaphcin-50Epirubicin Hydrochloride
50 mg Lyophilized Powder For Infusion (IV)25 mL USP Type I glass vial with grey bromobutyl rubber stopper and blue flip-off cap (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-13073
Nov 25, 2027
EpistarEpirubicin hydrochloride
50 mg Lyophilized Powder for Injection30 mL- capacity USP Type I clear moulded glass vial with bromobutyl slotted stopper and red color aluminum flip off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Healthwinds Medical Trading CorpImporter: Pharmastar Int'l Trading Corp.
DRP-14478-01
Feb 23, 2027
Epribenz-10Epirubicin hydrochloride
10 mg Lyophilized Powder for Injection5 mL- capacity USP Type I clear moulded glass vial with bromobutyl slotted rubber stopper and red color aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Pharmastar Int'l Trading Corp.
DRP-14475
Feb 23, 2027
Epribenz-10Epirubicin Hydrochloride
10mg Lyophilized Powder for Injection (IV/Intravesical)5 mL-capacity USP Type I clear moulded glass vial with bromobutyl slotted rubber stopper and red color aluminum flip-off seal (Box of 1's)
RxVAT-exempt
ADMAC LifesciencesIndia
Pharmastar Int'l Trading Corp.
DR-XY47750
Feb 23, 2027
Epribenz-50Epirubicin hydrochloride
50 mg Lyophilized Powder for Injection30 mL-capacity USP Type I clear moulded glass vial with bromobutyl slotted rubber stopper and red color aluminum flip off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Pharmastar Int'l Trading Corp.
DRP-14478
Feb 23, 2027
Epribenz-50Epirubicin Hydrochloride
50mg Lyophilized Powder for Injection (IV/Intravesical)30 mL-capacity USP Type I clear moulded glass vial with bromobutyl slotted rubber stopper and red color aluminum flip-off seal (Box of l’s)
RxVAT-exempt
ADMAC LifesciencesIndia
Pharmastar Int'l Trading Corp.
DR-XY47749
Feb 23, 2027
Erubixine-10Epirubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)5-mL capacity USP Type I Clear glass vial with bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International Corporation
DRP-11383
Mar 9, 2032
Erubixine-50Epirubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)30-mL capacity USP Type I Clear glass vial with bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Detoxicare Phils., Inc.Importer: Ambica International Corporation
DRP-11384
Mar 9, 2032
Helem-100Epirubicin hydrochloride
100 mg Lyophilized Powder for Solution for IV InfusionUSP Type I Clear Glass Vial (2 mg/mL concentrate solution when reconstituted with 50 mL diluent) (Box of 1's)
RxVAT-exempt
Celon Laboratories LimitedIndia
Kaufmann Pharma Inc.Importer: I.E. Medica, Inc.
DRP-7738-02
Mar 19, 2028
Helem-50Epirubicin Hydrochloride
50 mg Lyophilized Powder for Injection30 mL USP Type I Glass Vial (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Kaufmann Pharma Inc.Importer: I.E Medica Inc.
DRP-5841-02
Aug 8, 2029
Medirubicin-10Epirubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)5-mL capacity USP Type I Clear glass vial with bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Biologic Life Sciences Corp.Importer: Ambica International Corporation
DRP-11383-01
Mar 9, 2032
Medirubicin-50Epirubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)30-mL capacity USP Type I Clear glass vial with bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Biologic Life Sciences Corp.Importer: Ambica International Corporation
DRP-11384-02
Mar 9, 2032
NeoquabinEpirubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)USP Type I Clear and Colorless Glass Vial with Red Flip-off Seal (Box of 1's)
RxVAT-exempt
Korea United Pharm. Inc.Republic of Korea
Qualimed Pharma Inc.
DR-XY30170
Oct 21, 2029
NeoquabinEpirubicin Hydrochloride
50 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial with Red Flip-off seal Box of 1's
RxVAT-exempt
Korea United Pharm. Inc.Republic of Korea
Qualimed Pharma Inc.
DR-XY30171
Oct 21, 2029
NoneEpirubicin hydrochloride
100 mg Lyophilized Powder for Solution for IV InfusionUSP Type I Glass Vial (2 mg/mL concent rate solution when reconstituted with 50 mL). (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-7738-01
Mar 19, 2028
NoneEpirubicin hydrochloride
50 mg Lyophilized Powder for Injection30 mL USP Type I Glass Vial (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-5841-01
Aug 8, 2029
Pharmorubicin RDEpirubicin Hydrochloride
10 mg Powder for Injection (Intravenous/Intravesical)USP Type III Colorless Glass Vial with Chlorobutyl Rubber Stopper with 5 mL Water for Injection
RxVAT-exempt
Actavis Italy S.P.A.Italy
Importer: Pfizer, Inc.
DRP-2126
Sep 24, 2028
Pharmorubicin RDEpirubicin Hydrochloride
50 mg Powder for Injection (Intravenous/Intravesical)USP Type I Colorless glass vial with Chlorobutyl Rubber Stopper with 5mL Water for Injection (Box of 1's)
RxVAT-exempt
Actavis Italy S.P.A.Italy
Importer: Pfizer, Inc.
DRP-1992
Sep 24, 2028
PirubeneEpirubicin hydrochloride
50 mg Lyophilized Powder for Injection30 mL USP Type I Glass Vial (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix Inc.Importer: I.E Medica Inc.
DRP-5841-03
Aug 8, 2029
Pirusanz-10Epirubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)5-mL capacity USP Type I Clear glass vial with bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-11387
Mar 9, 2032
Pirusanz-50Epirubicin Hydrochloride
50mg Lyophilized Powder for Injection (IV)30-mL capacity USP Type I Clear glass vial with bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-11388
Mar 9, 2027
RubifonEpirubicin Hydrochloride
2 mg/mL (10 mg/5 mL) Concentrate solution for Injection (IV/Intravesical)6 mL-Capacity USP Type I Clear Glass Vial with Grey Chlorobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal x 5 mL (net content) (Box of 1's)
RxVAT-exempt
PT. Fonko International PharmaceuticalsIndonesia
Importer: Glorious Dexa Mandaya, Inc.
DRP-13532
Mar 8, 2028
RubifonEpirubicin Hydrochloride
2 mg/mL (50 mg/25 mL) Concentrate solution for Injection (IV/Intravesical)USP Type I Clear Glass Vial with Grey Chlorobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal x 25 mL (Box of 1's)
RxVAT-exempt
PT. Fonko International PharmaceuticalsIndonesia
Glorious Dexa Mandaya, Inc.
DRP-13531
Mar 8, 2028
RubilonEpirubicin hydrochloride
100 mg Lyophilized Powder for Solution for IV InfusionUSP Type I Clear Glass Vial (2 mg/mL concentrate solution when reconstituted with 50 mL diluent) Box of 1's
RxVAT-exempt
Celon Laboratories LimitedIndia
I.E. Medica, Inc.
DRP-7738
Mar 19, 2028
Rubilon 50Epirubicin hydrochloride
50 mg Lyophilized Powder for Injection30 mL USP Type I Glass Vial Box of 1 's
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E. Medica Inc.
DRP-5841
Aug 8, 2029
Rubilon-10Epirubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)In 10 mL-Capacity USP Type I Clear Glass Vial with Gray Bromo-butyl Rubber Stopper and Red Aluminum Flip-Off Seal (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-8850
Nov 10, 2030
Rubilon-10Epirubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)In 10 mL-Capacity USP Type I Clear Glass Vial with gray bromo-butyl rubber stopper and red aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E Medica Inc.
DRP-8851
Nov 10, 2030
Sanzepir-10Epirubicin (as hydrochloride)
10 mg Lyophilized Powder for Injection (IV)5 mL-capacity USP type I glass vial with bromobutyl rubber stopper and red flip-off seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-12539
Aug 30, 2032
Sanzepir-50Epirubicin (as hydrochloride)
50mg Lyophilized Powder for Injection (IV)In a 30 mL USP Type I glass vial with bromobutyl rubber stopper and red flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
AGB Pharmaceutical Trading & Consultancy CorporationImporter: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-13480
Feb 27, 2028
(no brand name)Epirubicin Hydrochloride
10 mg Lyophilized Powder For Injection (IV)5 mL Type I glass vial with grey butyl rubber stopper, aluminum seal and grey flip-off cap (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
Ve Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DRP-13118
Dec 2, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Injection: 50 mg/25 mL (2 mg/mL), 200 mg/100 mL (2 mg/mL) clear red solution in a single-dose vial. Injection: 50 mg/25 mL (2 mg/mL), 200 mg/100 mL (2 mg/mL) solution in single-dose vials (3).

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label

  • Use in Patients with Hepatic Impairment: Monitor serum total bilirubin and AST levels before and during treatment with ELLENCE. In patients with elevated serum AST or serum total bilirubin, dosage reductions or discontinuation may be required (2.3, 5.5).
  • Tumor Lysis Syndrome: Evaluate blood uric acid levels, potassium, calcium, phosphate, and creatinine after initial treatment. Consider hydration, urine alkalinization, and prophylaxis with allopurinol to minimize potential complications of hyperuricemia and tumor lysis syndrome (5.7).
  • Thrombophlebitis and Thromboembolic Events: Thrombophlebitis and thromboembolic events, including pulmonary embolism (in some cases fatal) have been reported with the use of ELLENCE. Venous sclerosis may result from an injection into a small vessel or from repeated injections into the same vein (5.9).
  • Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including ELLENCE, may result in serious or fatal infections (5.7).
  • Potentiation of Radiation Toxicity and Radiation Recall: Administration of ELLENCE after previous radiation therapy may induce an inflammatory recall reaction at the site of the irradiation (5.10).
  • Embryo-Fetal Toxicity: ELLENCE can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception (5.11, 8.1, 8.3).
5.1 Cardiac Toxicity

5.1 Cardiac Toxicity ELLENCE and other anthracycline drugs can result in either early (or acute) or late (delayed) cardiac toxicity. The principal manifestations of early cardiac toxicity are sinus tachycardia and/or electrocardiogram (ECG) abnormalities such as non-specific ST-T wave changes. However, tachycardia (including premature ventricular contractions and ventricular tachycardia), bradycardia, as well as atrioventricular and bundle-branch block have been reported.

Early cardiac toxicity does not usually predict the subsequent occurrence of delayed cardiotoxicity and generally should not be considered a reason for suspending treatment with ELLENCE. Delayed cardiac toxicity is manifested by reduced left ventricular ejection fraction (LVEF) and/or signs and symptoms of congestive heart failure (CHF).

If it occurs, late cardiotoxicity usually develops late during therapy with ELLENCE or within 2 to 3 months after completion of treatment, but there are reports of it occurring several months to years after treatment termination. In a retrospective survey, including 9144 patients, mostly with solid tumors in advanced stages, the probability of developing CHF increased with increasing cumulative doses of ELLENCE (Figure 1).

In another retrospective survey of 469 ELLENCE-treated patients with metastatic or early breast cancer, the reported risk of CHF was comparable to that observed in the larger study of over 9000 patients. Given the risk of cardiac toxicity, cumulative doses of 900 mg/m 2 ELLENCE should generally be avoided. Figure 1. Risk of CHF in 9144 Patients Treated with ELLENCE Prior history of cardiovascular disease, prior or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, and concomitant use of other cardiotoxic drugs, increase the risk of developing late cardiac toxicity.

Avoid administration of ELLENCE in combination with other cardiotoxic drugs. Although not formally tested, it is probable that the toxicity of ELLENCE and other anthracyclines or anthracenediones is additive. Cardiac toxicity with ELLENCE may occur at lower cumulative doses whether or not cardiac risk factors are present.

Patients receiving ELLENCE after stopping treatment with other cardiotoxic drugs, especially those with long half-lives such as trastuzumab, may be at increased risk of developing cardiotoxicity [see Dosage and Administration (2) and Drug Interaction (7.1)]. Perform a baseline ECG and evaluation of LVEF prior to initiating treatment with ELLENCE.

Monitor LVEF during the course of treatment and consider discontinuation of ELLENCE if LVEF decrease and/or signs or symptoms of CHF develop. Closely monitor patients with other risk factors for cardiac toxicity, particularly prior administration of anthracycline or anthracenedione. Figure 1

5.2 Secondary Malignancies

5.2 Secondary Malignancies The risk of developing secondary acute myelogenous leukemia and myelodysplastic syndrome (MDS), is increased following treatment with ELLENCE and other anthracyclines. Cumulative risk of secondary acute myelogenous leukemia or myelodysplastic syndrome (AML/MDS) of about 0.27% at 3 years, 0.46% at 5 years, and 0.55% at 8 years.

These leukemias generally occur within 1 to 3 years of treatment [see Adverse Reactions (6.1)].

5.3 Extravasation and Tissue Necrosis

5.3 Extravasation and Tissue Necrosis Extravasation of ELLENCE can result in severe local tissue injury manifesting as blistering, ulceration, and necrosis requiring wide excision of the affected area and skin grafting. Extravasation should be considered if a patient experiences a burning or stinging sensation or shows other evidence indicating peri-venous infiltration or extravasation; however, extravasation may be present in patients who do not experience a stinging or burning sensation or when blood return is present on aspiration of the infusion needle.

Venous sclerosis may result from an injection into a small vessel or from repeated injections into the same vein. Administer ELLENCE slowly into the tubing of a freely running intravenous infusion. Patients receiving initial therapy at the recommended starting doses of 100–120 mg/m 2 should have ELLENCE infused over 15–20 minutes.

For patients who require lower ELLENCE starting doses due to organ dysfunction or who require modification of ELLENCE doses during therapy, the ELLENCE infusion time may be proportionally decreased, but should not be less than 3 minutes [see Dosage and Administration (2.3)]. If possible, avoid veins over joints or in extremities with compromised venous or lymphatic drainage.

Facial flushing, as well as local erythematous streaking along the vein, may be indicative of excessively rapid administration. It may precede local phlebitis or thrombophlebitis. Immediately terminate infusion and restart in another vein if a burning or stinging sensation indicates perivenous infiltration. Perivenous infiltration may occur without causing pain.

If extravasation is suspected, immediately discontinue the intravenous injection or continuous intravenous infusion [see Dosage and Administration (2.3)]. Apply ice to the site intermittently for 15 minutes, 4 times a day for 3 days. If appropriate, administer dexrazoxane at the site of extravasation as soon as possible and within the first 6 hours after extravasation.

5.4 Severe Myelosuppression

5.4 Severe Myelosuppression ELLENCE can cause severe myelosuppression [see Adverse Reactions (6.1). Obtain complete blood counts prior to each treatment and carefully monitor patients during treatment for possible clinical complications due to myelosuppression. Delay the next dose of ELLENCE if severe myelosuppression has not improved.

Consider dose reduction for patients with prolonged myelosuppression based on the severity of reaction [see Dosage and Administration (2.3)].

5.5 Use in Patients with Hepatic Impairment

5.5 Use in Patients with Hepatic Impairment The major route of elimination of epirubicin is the hepatobiliary system [see Clinical Pharmacology (12.3)]. Evaluate serum total bilirubin and AST levels before and during treatment with ELLENCE. Patients with elevated bilirubin or AST may experience slower clearance of drug with an increase in overall toxicity.

Lower doses are recommended in these patients [see Dosage and Administration (2.2)]. Patients with severe hepatic impairment have not been evaluated; therefore, do not use ELLENCE in this patient population [see Contraindications (4)].

5.6 Use in Patients with Renal Impairment

5.6 Use in Patients with Renal Impairment Assess serum creatinine before and during therapy. Dosage adjustment is necessary in patients with serum creatinine >5 mg/dL [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]. Patients undergoing dialysis have not been studied.

5.7 Tumor-Lysis Syndrome

5.7 Tumor-Lysis Syndrome ELLENCE can induce tumor lysis syndrome in patients with rapidly growing tumors. Evaluate blood uric acid levels, potassium, calcium, phosphate, and creatinine after initial treatment. Consider hydration, urine alkalinization, and prophylaxis with allopurinol to minimize hyperuricemia and potential complications of tumor lysis syndrome.

5.8 Immunosuppressant Effects/Increased Susceptibility to Infections

5.8 Immunosuppressant Effects/Increased Susceptibility to Infections Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including epirubicin, may result in serious or fatal infections. Avoid vaccination with a live vaccine in patients receiving ELLENCE. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.

5.9 Thrombophlebitis

5.9 Thrombophlebitis and Thromboembolic Events Thrombophlebitis and thromboembolic events, including pulmonary embolism (in some cases fatal) have been reported with the use of ELLENCE.

5.10 Potentiation of Radiation Toxicity

5.10 Potentiation of Radiation Toxicity and Radiation Recall ELLENCE can increase radiation-induced toxicity to the myocardium, mucosa, skin, and liver. Radiation recall, including but not limited to cutaneous and pulmonary toxicity, can occur in patients who receive ELLENCE after prior radiation therapy.

5.11 Embryo-Fetal Toxicity

5.11 Embryo-Fetal Toxicity Based on findings from animals and its mechanism of action, ELLENCE can cause fetal harm when administered to a pregnant woman; avoid the use of ELLENCE during the 1 st trimester. Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of epirubicin during the 2 nd and 3 rd trimesters.

In animal reproduction studies, epirubicin was embryo-fetal lethal and caused structural abnormalities in rats and rabbits at doses less than the maximum recommended human dose on a body surface area basis. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise female patients of reproductive potential to use effective contraception during treatment and for 6 months after the last dose of ELLENCE.

Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of ELLENCE. Advise male patients with pregnant partners to use condoms during treatment and for at least 7 days after the last dose of ELLENCE [see Use in Specific Populations (8.1, 8.3), Clinical Pharmacology (12.1), and Nonclinical Toxicology (13.1)].

Drug interactions

Drug interactions (US label) US FDA label

  • Avoid using cardiotoxic agents in combination with ELLENCE (7.1).
  • Discontinue cimetidine during treatment with ELLENCE (7.2).
7.1 Cardiotoxic Agents

7.1 Cardiotoxic Agents Closely monitor cardiac function when ELLENCE is used in combination with other cardiotoxic agents. Patients receiving ELLENCE after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as trastuzumab, may be at an increased risk of developing cardiotoxicity [see Dosage and Administration (2) and Warnings and Precautions (5.1)].

Trastuzumab may persist in the circulation for up to 7 months. Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. Monitor the patient's cardiac function closely if anthracyclines are used before this time. Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.

7.2 Cimetidine

7.2 Cimetidine Cimetidine increases the exposure to epirubicin [see Clinical Pharmacology (12.3)]. Discontinue cimetidine during treatment with ELLENCE.

7.3 Other Cytotoxic Drugs

7.3 Other Cytotoxic Drugs ELLENCE used in combination with other cytotoxic drugs may show on-treatment additive toxicity, especially hematologic and gastrointestinal effects. Paclitaxel: The administration of epirubicin immediately prior to or after paclitaxel increased the systemic exposure of epirubicin, epirubicinol and 7-deoxydoxorubicin aglycone [see Clinical Pharmacology (12.3)].

Docetaxel: The administration of epirubicin immediately prior to or after docetaxel did not have an effect on the systemic exposure of epirubicin, but increased the systemic exposure of epirubicinol and 7-deoxydoxorubicin aglycone [see Clinical Pharmacology (12.3)].

7.4 Radiation Therapy

7.4 Radiation Therapy There are few data regarding the coadministration of radiation therapy and ELLENCE. In adjuvant trials of ELLENCE-containing CEF-120 or FEC-100 chemotherapies, breast irradiation was delayed until after chemotherapy was completed. This practice resulted in no apparent increase in local breast cancer recurrence relative to published accounts in the literature.

A small number of patients received ELLENCE-based chemotherapy concomitantly with radiation therapy but had chemotherapy interrupted in order to avoid potential overlapping toxicities. It is likely that use of ELLENCE with radiotherapy may sensitize tissues to the cytotoxic actions of irradiation. Administration of ELLENCE after previous radiation therapy may induce an inflammatory recall reaction at the site of the irradiation.

Adverse reactions

Adverse reactions (US label) US FDA label

The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Cardiac Toxicity [see Warnings and Precautions (5.1)]
  • Secondary Malignancies [see Warnings and Precautions (5.2)]
  • Extravasation and Tissue Necrosis [see Warnings and Precautions (5.3)]
  • Severe Myelosuppression [see Warnings and Precautions (5.4)]
  • Tumor-Lysis Syndrome [see Warnings and Precautions (5.7)]
  • Thrombophlebitis and Thromboembolic Events [see Warnings and Precautions (5.9)]
  • Potentiation of Radiation Toxicity and Radiation Recall [see Warnings and Precautions (5.10)] The most common adverse reactions (≥10%) are leukopenia, neutropenia, anemia, thrombocytopenia, amenorrhea, lethargy, nausea/vomiting, mucositis, diarrhea, infection, conjunctivitis/keratitis, alopecia, local skin toxicity, and rash/itch (6). To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ELLENCE was evaluated in two studies (Studies MA-5 and GFEA-05) evaluating combination regimens in patients with early breast cancer [see Clinical Studies (14.1)].

Of the 1260 patients treated in these studies, 620 patients received the higher-dose ELLENCE regimen (FEC-100/CEF-120), 280 patients received the lower-dose ELLENCE regimen (FEC-50), and 360 patients received CMF. Serotonin-specific antiemetic therapy and colony-stimulating factors were not used in these trials. Clinically relevant adverse reactions are summarized in Table 1.

Table 1. Adverse Reactions in Patients with Early Breast Cancer Event % of Patients FEC-100/CEF-120 (N=620) FEC-50 (N=280) CMF (N=360) Grades 1–4 Grades 3/4 Grades 1–4 Grades 3/4 Grades 1–4 Grades 3/4 FEC & CEF = cyclophosphamide + ELLENCE + fluorouracil; CMF = cyclophosphamide + methotrexate + fluorouracil; NA = not available Grade 1 or 2 changes in transaminase levels were observed but were more frequently seen with CMF than with CEF.

Hematologic Leukopenia 80 59 50 1.5 98 60 Neutropenia 80 67 54 11 96 78 Anemia 72 6 13 0 71 0.9 Thrombocytopenia 49 5 4.6 0 51 3.6 Endocrine Amenorrhea 72 0 69 0 68 0 Hot flashes 39 4 5 0 69 6 Body as a Whole Lethargy 46 1.9 1.1 0 73 0.3 Fever 5 0 1.4 0 4.5 0 Gastrointestinal Nausea/vomiting 92 25 83 22 85 6 Mucositis 59 9 9 0 53 1.9 Diarrhea 25 0.8 7 0 51 2.8 Anorexia 2.9 0 1.8 0 6 0.3 Infection Infection 22 1.6 15 0 26 0.6 Febrile neutropenia NA 6 0 0 NA 1.1 Ocular Conjunctivitis/keratitis 15 0 1.1 0 38 0 Skin Alopecia 96 57 70 19 84 7 Local toxicity 20 0.3 2.5 0.4 8 0 Rash/itch 9 0.3 1.4 0 14 0 Skin changes 4.7 0 0.7 0 7 0 Delayed Events Table 2 describes the incidence of delayed adverse reactions in patients participating in the MA-5 and GFEA-05 trials. Table 2.

Long-Term Adverse Reactions in Patients with Early Breast Cancer Event % of Patients FEC-100/CEF-120 (N=620) FEC-50 (N=280) CMF (N=360) Two cases of acute lymphoid leukemia (ALL) were also observed in patients receiving ELLENCE. However, an association between anthracyclines such as ELLENCE and ALL has not been clearly established.

Cardiac events Asymptomatic drops in LVEF 2.1 In study MA-5, cardiac function was not monitored after 5 years. 1.4 0.8 CHF 1.5 0.4 0.3 Leukemia AML 0.8 0 0.3 Hematologic Dose-dependent, reversible leukopenia and/or neutropenia is the predominant manifestation of hematologic toxicity associated with ELLENCE and represents the most common acute dose-limiting toxicity of this drug. In most cases, the white blood cell (WBC) nadir is reached 10 to 14 days from drug administration.

Leukopenia/neutropenia is usually transient, with WBC and neutrophil counts generally returning to normal values by Day 21 after drug administration. As with other cytotoxic agents, ELLENCE at the recommended dose in combination with cyclophosphamide and fluorouracil can produce severe leukopenia and neutropenia. Severe thrombocytopenia and anemia may also occur.

Clinical consequences of severe myelosuppression include fever, infection, septicemia, septic shock, hemorrhage, tissue hypoxia, symptomatic anemia, or death. If myelosuppressive complications occur, use appropriate supportive measures (e.g., intravenous antibiotics, colony-stimulating factors, transfusions). Myelosuppression requires careful monitoring.

Assess total and differential WBC, red blood cell (RBC), and platelet counts before and during each cycle of therapy with ELLENCE [see Warnings and Precautions (5.4)]. Gastrointestinal A dose-dependent mucositis (mainly oral stomatitis, less often esophagitis) may occur in patients treated with ELLENCE. Clinical manifestations of mucositis may include a pain or burning sensation, erythema, erosions, ulcerations, bleeding, or infections.

Mucositis generally appears early after drug administration and, if severe, may progress over a few days to mucosal ulcerations; most patients recover from this adverse event by the third week of therapy. Hyperpigmentation of the oral mucosa may also occur. Nausea, vomiting, and occasionally diarrhea and abdominal pain can also occur.

Severe vomiting and diarrhea may produce dehydration. Antiemetics may reduce nausea and vomiting; consider prophylactic use of antiemetics before therapy [see Dosage and Administration (2.1)]. Cutaneous and Hypersensitivity Reactions Alopecia occurs frequently, but is usually reversible, with hair regrowth occurring within 2 to 3 months from the termination of therapy.

Flushes, skin and nail hyperpigmentation, photosensitivity, and hypersensitivity to irradiated skin (radiation-recall reaction) have been observed. Urticaria and anaphylaxis have been reported in patients treated with ELLENCE; signs and symptoms of these reactions may vary from skin rash and pruritus to fever, chills, and shock.

Cardiovascular Serious drug-related cardiovascular adverse events that occurred during clinical trials with ELLENCE, administered in different indications, include ventricular tachycardia, AV block, bundle branch block, bradycardia and thromboembolism. Secondary Leukemia An analysis of 7110 patients who received adjuvant treatment with ELLENCE in controlled clinical trials as a component of poly-chemotherapy regimens for early breast cancer, showed a cumulative risk of secondary acute myelogenous leukemia or myelodysplastic syndrome (AML/MDS) of about 0.27% (approximate 95% CI, 0.14–0.40) at 3 years, 0.46% (approximate 95% CI, 0.28–0.65) at 5 years, and 0.55% (approximate 95% CI, 0.33–0.78) at 8 years.

The risk of developing AML/MDS increased with increasing ELLENCE cumulative doses as shown in Figure 2. Figure 2. Risk of AML/MDS in 7110 Patients Treated with ELLENCE The cumulative probability of developing AML/MDS was found to be particularly increased in patients who received more than the maximum recommended cumulative dose of ELLENCE (720 mg/m 2) or cyclophosphamide (6,300 mg/m 2), as shown in Table 3.

Table 3. Cumulative Probability of AML/MDS in Relation to Cumulative Doses of ELLENCE and Cyclophosphamide Years from Treatment Start Cumulative Probability of Developing AML/MDS % (95% CI) Cyclophosphamide Cumulative Dose ≤6,300 mg/m 2 Cyclophosphamide Cumulative Dose >6,300 mg/m 2 ELLENCE Cumulative Dose ≤720 mg/m 2 N=4760 ELLENCE Cumulative Dose >720 mg/m 2 N=111 ELLENCE Cumulative Dose ≤720 mg/m 2 N=890 ELLENCE Cumulative Dose >720 mg/m 2 N=261 3 0.12 (0.01–0.22) 0.00 (0.00–0.00) 0.12 (0.00–0.37) 4.37 (1.69–7.05) 5 0.25 (0.08–0.42) 2.38 (0.00–6.99) 0.31 (0.00–0.75) 4.97 (2.06–7.87) 8 0.37 (0.13–0.61) 2.38 (0.00–6.99) 0.31 (0.00–0.75) 4.97 (2.06–7.87) Figure 2

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ELLENCE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Infections and infestations: sepsis, pneumonia Immune system disorders: anaphylaxis Metabolism and nutrition disorders: dehydration, hyperuricemia Vascular disorders: shock, hemorrhage, embolism arterial, thrombophlebitis, phlebitis Respiratory, thoracic and mediastinal disorders: pulmonary embolism Gastrointestinal disorders: erosions, ulcerations, pain or burning sensation, bleeding, hyperpigmentation of the oral mucosa Skin and subcutaneous tissue disorders: erythema, flushes, skin and nail hyperpigmentation, photosensitivity, hypersensitivity to irradiated skin (radiation-recall reaction), urticaria Renal and urinary disorders: red coloration of urine for 1 to 2 days after administration General disorders and administration site conditions: fever, chills Injury, poisoning and procedural complications: chemical cystitis (following intravesical administration)

Adverse reaction frequency tables (US label) US FDA label
Table 1. Adverse Reactions in Patients with Early Breast Cancer
Event% of Patients
FEC-100/CEF-120 (N=620)FEC-50 (N=280)CMF (N=360)
Grades 1–4Grades 3/4Grades 1–4Grades 3/4Grades 1–4Grades 3/4
FEC & CEF = cyclophosphamide + ELLENCE + fluorouracil; CMF = cyclophosphamide + methotrexate + fluorouracil; NA = not available
Grade 1 or 2 changes in transaminase levels were observed but were more frequently seen with CMF than with CEF.
Hematologic
Leukopenia8059501.59860
Neutropenia806754119678
Anemia726130710.9
Thrombocytopenia4954.60513.6
Endocrine
Amenorrhea720690680
Hot flashes39450696
Body as a Whole
Lethargy461.91.10730.3
Fever501.404.50
Gastrointestinal
Nausea/vomiting92258322856
Mucositis59990531.9
Diarrhea250.870512.8
Anorexia2.901.8060.3
Infection
Infection221.6150260.6
Febrile neutropeniaNA600NA1.1
Ocular
Conjunctivitis/keratitis1501.10380
Skin
Alopecia96577019847
Local toxicity200.32.50.480
Rash/itch90.31.40140
Skin changes4.700.7070
Table 2. Long-Term Adverse Reactions in Patients with Early Breast Cancer
Event% of Patients
FEC-100/CEF-120 (N=620)FEC-50 (N=280)CMF (N=360)
Two cases of acute lymphoid leukemia (ALL) were also observed in patients receiving ELLENCE. However, an association between anthracyclines such as ELLENCE and ALL has not been clearly established.
Cardiac events
Asymptomatic drops in LVEF2.1In study MA-5, cardiac function was not monitored after 5 years.1.40.8
CHF1.50.40.3
Leukemia
AML0.800.3
Table 3. Cumulative Probability of AML/MDS in Relation to Cumulative Doses of ELLENCE and Cyclophosphamide
Years from Treatment StartCumulative Probability of Developing AML/MDS % (95% CI)
Cyclophosphamide Cumulative Dose ≤6,300 mg/m2Cyclophosphamide Cumulative Dose >6,300 mg/m2
ELLENCE Cumulative Dose ≤720 mg/m2 N=4760ELLENCE Cumulative Dose >720 mg/m2 N=111ELLENCE Cumulative Dose ≤720 mg/m2 N=890ELLENCE Cumulative Dose >720 mg/m2 N=261
30.12 (0.01–0.22)0.00 (0.00–0.00)0.12 (0.00–0.37)4.37 (1.69–7.05)
50.25 (0.08–0.42)2.38 (0.00–6.99)0.31 (0.00–0.75)4.97 (2.06–7.87)
80.37 (0.13–0.61)2.38 (0.00–6.99)0.31 (0.00–0.75)4.97 (2.06–7.87)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, ELLENCE can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]; avoid the use of ELLENCE during the 1 st trimester. Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of epirubicin during the 2 nd and 3 rd trimesters.

There are reports of fetal and/or neonatal cardiotoxicity following in utero exposure to epirubicin (see Clinical Considerations). In animal reproduction studies in pregnant rats, epirubicin was embryo-fetal lethal and caused structural abnormalities when administered during organogenesis at doses less than the maximum recommended human dose on a body surface area basis (see Data).

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations Fetal/Neonatal Adverse Reactions There have been rare reports of fetal and/or neonatal transient ventricular hypokinesia, transient elevation of cardiac enzymes, and a case of fetal demise from suspected anthracycline-induced cardiotoxicity following in utero exposure to epirubicin in 2 nd and/or 3 rd trimesters. Cardiotoxicity is a known risk of anthracycline treatment in adults [see Warnings and Precautions (5.1)].

Monitor the fetus and/or neonate for cardiotoxicity and perform testing consistent with community standards of care. Data Animal Data Intravenous administration of 0.8 mg/kg/day epirubicin (about 0.04 times the maximum recommended single human dose on a body surface area basis) to rats during Days 5 to 15 of gestation resulted in embryofetal lethality (increased resorptions and post-implantation loss) and caused fetal growth retardation (decreased body weight).

Intravenous administration of 2 mg/kg/day epirubicin (about 0.1 times the maximum recommended single human dose on a body surface area basis) to rats on Days 9 and 10 of gestation resulted in embryo-fetal lethality (increased late resorptions, post-implantation losses, and dead fetuses; and decreased live fetuses), retarded fetal growth (decreased body weight), and caused decreased placental weight and numerous external (anal atresia, misshapen tail, abnormal genital tubercle), visceral (primarily gastrointestinal, urinary, and cardiovascular systems), and skeletal (deformed long bones and girdles, rib abnormalities, irregular spinal ossification) malformations. Administration of intravenous epirubicin to rabbits at doses up to 0.2 mg/kg/day (about 0.02 times the maximum recommended single human dose on a body surface area basis) during Days 6 to 18 of gestation was not teratogenic, but a maternally toxic dose of 0.32 mg/kg/day increased abortions and delayed ossification.

Administration of a maternally toxic intravenous dose of 1 mg/kg/day epirubicin to rabbits (about 0.1 times the maximum recommended single human dose on a body surface area basis) on Days 10 to 12 of gestation induced abortion, but no other signs of teratogenicity were observed. When doses up to 0.5 mg/kg/day epirubicin were administered to rat dams from Day 17 of gestation to Day 21 after delivery (about 0.025 times the maximum recommended single human dose on a body surface area basis), no permanent changes were observed in the development, functional activity, behavior, or reproductive performance of the offspring.

Mechanism of action

12.1 Mechanism of Action Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated.

Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription.

Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors.

It is also active in vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Excretion Epirubicin and its major metabolites are eliminated through biliary excretion and, to a lesser extent, by urinary excretion.

Effect of Hepatic Impairment Epirubicin is eliminated by both hepatic metabolism and biliary excretion and clearance is reduced in patients with hepatic dysfunction.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Epirubicin pharmacokinetics are linear over the dose range of 60 to 150 mg/m 2 and plasma clearance is not affected by the duration of infusion or administration schedule. Pharmacokinetic parameters for epirubicin following 6- to 10-minute, single-dose intravenous infusions of ELLENCE at doses of 60 to 150 mg/m 2 in patients with solid tumors are shown in Table 4.

The plasma concentration declined in a triphasic manner with mean half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours, and 33 hours, respectively. Table 4. Summary of Mean (±SD) Pharmacokinetic Parameters in Patients Advanced solid tumor cancers, primarily of the lung with Solid Tumors Receiving Intravenous ELLENCE 60 to 150 mg/m 2 Dose N=6 patients per dose level (mg/m 2) C max Plasma concentration at the end of 6 to 10 minutes infusion (µg/mL) AUC Area under the plasma concentration curve (µg∙h/mL) t 1/2 Half-life of terminal phase (hours) CL Plasma clearance (L/hour) Vss Steady state volume of distribution (L/kg) 60 5.7 ± 1.6 1.6 ± 0.2 35.3 ± 9 65 ± 8 21 ± 2 75 5.3 ± 1.5 1.7 ± 0.3 32.1 ± 5 83 ± 14 27 ± 11 120 9.0 ± 3.5 3.4 ± 0.7 33.7 ± 4 65 ± 13 23 ± 7 150 9.3 ± 2.9 4.2 ± 0.8 31.1 ± 6 69 ± 13 21 ± 7 Distribution Following intravenous administration, epirubicin is rapidly and widely distributed into the tissues.

Binding of epirubicin to plasma proteins, predominantly albumin, is about 77% and is not affected by drug concentration. Epirubicin also appears to concentrate in red blood cells; whole blood concentrations are approximately twice those of plasma. Metabolism Epirubicin is extensively and rapidly metabolized by the liver and is also metabolized by other organs and cells, including red blood cells.

Four main metabolic routes have been identified: (1) reduction of the C-13 keto-group with the formation of the 13(S)-dihydro derivative, epirubicinol; (2) conjugation of both the unchanged drug and epirubicinol with glucuronic acid; (3) loss of the amino sugar moiety through a hydrolytic process with the formation of the doxorubicin and doxorubicinol aglycones; and (4) loss of the amino sugar moiety through a redox process with the formation of the 7-deoxy-doxorubicin aglycone and 7-deoxy-doxorubicinol aglycone. Epirubicinol has in vitro cytotoxic activity one-tenth that of epirubicin.

As plasma levels of epirubicinol are lower than those of the unchanged drug, they are unlikely to reach in vivo concentrations sufficient for cytotoxicity. No significant activity or toxicity has been reported for the other metabolites. Excretion Epirubicin and its major metabolites are eliminated through biliary excretion and, to a lesser extent, by urinary excretion.

Mass-balance data from 1 patient found about 60% of the total radioactive dose in feces (34%) and urine (27%). These data are consistent with those from 3 patients with extrahepatic obstruction and percutaneous drainage, in whom approximately 35% and 20% of the administered dose were recovered as epirubicin or its major metabolites in bile and urine, respectively, in the 4 days after treatment.

Effect of Age A population analysis of plasma data from 36 cancer patients (13 males and 23 females, 20 to 73 years) showed that age affects plasma clearance of epirubicin in female patients. The predicted plasma clearance for a female patient of 70 years of age was about 35% lower than that for a female patient of 25 years of age.

An insufficient number of males > 50 years of age were included in the study to draw conclusions about age-related alterations in clearance in males. Although a lower ELLENCE starting dose does not appear necessary in elderly female patients, and was not used in clinical trials, particular care should be taken in monitoring toxicity when ELLENCE is administered to female patients > 70 years of age.

Effect of Gender In patients ≤ 50 years of age, mean clearance values in adult male and female patients were similar. The clearance of epirubicin is decreased in elderly women. Effect of Race The influence of race on the pharmacokinetics of epirubicin has not been evaluated. Effect of Hepatic Impairment Epirubicin is eliminated by both hepatic metabolism and biliary excretion and clearance is reduced in patients with hepatic dysfunction.

In a study of the effect of hepatic dysfunction, patients with solid tumors were classified into 3 groups. Patients in Group 1 (n=22) had serum AST (SGOT) levels above the upper limit of normal (median: 93 IU/L) and normal serum bilirubin levels (median: 0.5 mg/dL) and were given ELLENCE doses of 12.5 to 90 mg/m 2. Patients in Group 2 had alterations in both serum AST (median: 175 IU/L) and bilirubin levels (median: 2.7 mg/dL) and were treated with an ELLENCE dose of 25 mg/m 2 (n=8).

Their pharmacokinetics were compared to those of patients with normal serum AST and bilirubin values, who received ELLENCE doses of 12.5 to 120 mg/m 2. The median plasma clearance of epirubicin was decreased compared to patients with normal hepatic function by about 30% in patients in Group 1 and by 50% in patients in Group 2.

Patients with more severe hepatic impairment have not been evaluated [see Dosage and Administration (2.3), and Warnings and Precautions (5.5)]. Effect of Renal Impairment No significant alterations in the pharmacokinetics of epirubicin or its major metabolite, epirubicinol, have been observed in patients with serum creatinine < 5 mg/dL.

A 50% reduction in plasma clearance was reported in four patients with serum creatinine ≥ 5 mg/dL [see Warnings and Precautions (5.6) and Dosing and Administration (2.2)]. Patients on dialysis have not been studied. Effect of Paclitaxel The administration of paclitaxel (175–225 mg/m 2 as a 3-hour infusion) immediately before or after epirubicin (90 mg/m 2 as bolus) caused variable increases in the systemic exposure (mean AUC) of epirubicin ranging from 5% to 109%.

At same doses of epirubicin and paclitaxel, the mean AUC of the inactive metabolites of epirubicin (epirubicinol and 7-deoxy-aglycone) increased by 120% and 70%, respectively, when paclitaxel was immediately administered after epirubicin. Epirubicin had no effect on the exposure of paclitaxel whether it was administered before or after paclitaxel.

Effect of Docetaxel The administration of docetaxel (70 mg/m 2 as 1-hour infusion) immediately before or after epirubicin (90 mg/m 2 as bolus) had no effect on the systemic exposure (mean AUC) of epirubicin. However, the mean AUC of epirubicinol and 7-deoxy-aglycone increased by 22.5% and 95%, respectively, when docetaxel was immediately administered after epirubicin compared to epirubicin alone.

Epirubicin had no effect on the exposure of docetaxel whether it was administered before or after docetaxel. Effect of Cimetidine Coadministration of cimetidine (400 mg twice daily for 7 days starting 5 days before chemotherapy) increased the mean AUC of epirubicin (100 mg/m 2) by 50% and decreased its plasma clearance by 30%.

Drugs metabolized by cytochrome P-450 enzymes No systematic in vitro or in vivo evaluation has been performed to examine the potential for inhibition or induction by epirubicin of oxidative cytochrome P-450 isoenzymes.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Epirubicin 50 mg Vial₱1,600.00–₱2,677.00Reference ₱1,600.00per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Epirubicin (as hydrochloride)
PNF listingInj.: powder, 10 mg and 50 mg vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Ellence · Pharmacia & Upjohn Company LLC [US FDA-approved label, version 26, July 24, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a03c798-a652-4895-b29c-3b521a89ba42
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .